Reddit Posts
If you had $40k to invest right now, what would you do with it?
Vertex Pharma (VRTX)-the next Blockbuster for 2024
Vertex (VRTX) reports positive results for its non-opioid pain killer
CRSP FDA Approval Deadline Dec 8.
SPECIAL DATES IN MEDICAL HISTORY **NEXT MONTH**= FDA DECISIONS= Dec 8th 2023 FOR $CRSP & Dec 20th 2023 FOR $BLUE-Aprvd in UK Last Week.
CRSP Stock Surges after winning the first ever gene editing approval
$CRSP CRISPR Therapeutics pending EMA and FDA Aprovel
Vertex in pact with ImmunoGen to expand gene editing reach (NASDAQ:VRTX)
MULN, NIO Stock Speculations. TSLA Stock Blitzed. BIIB CRSP & VRTX Stock...
Recession has been here (proof inside)
The biotech rocket getting ready for launch - $CRSP Crispr Therapeutics DD
RIP NASDAQ 100 - Jim Cramer says investors should eye these three tech names in the Nasdaq 100
$CBIO up over 100% on news it’s selling a chunk of its portfolio to $VRTX for 60mm
Thoughts on the housing market / equities from an old school WSBer.
told you guys, but there is still time
Searing Criticism on ARK's Genomic Bets in FT. What do you think?
Regeneron (REGN), Thermo Fischer (TMO), Danaher (DHR) and Vertex (VRTX)
Vertex Pharmecuticals (VRTX) Discussion
Wells Fargo says correction is likely, recommend these 10 safe picks (RH? UAA?)
How much do you think a cure for Diabetes will make?
Barrons Stocks to Own April 13, 2020 update
$VRTX $PTON $PDD - Wall Street Says: Buy These 3 Nasdaq Stocks On The Dip
Should I buy Vertex ($VRTX)? Good company with strong fundamentals & good value.
Should I buy Vertex ($VRTX) at these levels? Strong company with good fundamentals.
Eloxx Pharmaceuticals (ELOX) DD - Biopharma play with Major Insider Buying and 100x upside
$VRTX is a DEEP VALUE Biotech Cash-Flow Machine
CELZ Potential To Return 13,800% In 3-5 Years
$NTLA and $REGN announce that they have successfully corrected a hereditary disease with an infusion of CRISPR
$NTLA and $REGN announce that they have successfully corrected a hereditary disease with an infusion of CRISPR
2 Stocks That Are Flirting With a Bottom; Analysts Say ‘Buy’
VRTX pick it up on discount while you still can
Looking to invest in healthcare: Should I go with the PSCH ETF or invest in $VRTX stock?
Viatris (VTRS) recommended as one of 5 v undervalued Pharma stocks in Barrons today
Mentions
Could be - I see the spike on the VRTX chart too, and it was mostly pharma stocks I saw it on
Possibly related to the VRTX acquisition yesterday. Making funds rebalance.
Apparel and Textile Importers/Exporters: The TJX Companies, Inc. (NYSE: TJX), headquartered in Framingham, Massachusetts, TJX is a major retailer that imports and exports apparel and home goods. Specialty Retailers: Wayfair Inc. (NYSE: W), an e-commerce company headquartered in Boston, specializing in home goods and furnishings. Pharmaceutical Companies: Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), a biopharmaceutical company headquartered in Boston, focusing on the discovery and development of small molecule drugs for the treatment of serious diseases. Analog Devices, Inc. (NASDAQ: ADI), headquartered in Norwood, Massachusetts, Analog Devices designs and manufactures semiconductor products used in various industries, including technology and electronics Biotechnology Companies: Biogen Inc. (NASDAQ: BIIB), a biotechnology company headquartered in Cambridge, Massachusetts, specializing in the discovery, development, and commercialization of therapies for neurological and neurodegenerative diseases.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-407, an investigational first-in-class small molecule corrector that targets the underlying cause of autosomal dominant polycystic kidney disease (ADPKD) in patients with a subset of PKD1 genetic variants. Very early stages, but I love seeing the company keep innovating.
VRTX better product than NVO wegovy and LLY Zepbound and they have a superior NASH drug compared to MDGL?? No brainer long VKTX since $17.92. VKTX $200 stonk soon
Any murmurs with VRTX or GSK going into this week? missed the NVO bus and want to play between AI and pharma for stabilization.
I should hop in on the VRT calls for 100-110s i think thats very doable. whats your stance with VRTX heard some rumors like with NVO on a drug approval.
REGN Regeneron Pharmaceutics TECH Bio-Techne Corporation VRTX Vertex Pharmaceuticals no idea about prices or how they are doing in the past couple of months
Right. Because VRTX medications for Cystic Fibrosis is "sexy".
Realistically, yes you're right. Looking at the recent earnings guidance CRSP and VRTX both said they have a payer already covering 100M patients in US and Europe. I assume Saudis will use oil money for now. The point is, even if they are able to capture 1% of this market over 3 years. It's still substantial revenue that will propel the stock to a valuation of 100B or higher. With them getting approvals quickly I expect no less in Canada and Switzerland, along with other regions. The point overall is, holding CRSP is no longer risky. They have a real product, real revenue potential, and an exciting pipeline that isn't at risk of fizzling out due to lack of funds over the next decade.
Congrats on your gains and really awesome entry. But my point is, VKTX Viking therapeutics is not a genetic engineering company like CRSP EDIT etc. It’s an obesity company with a GLP1 like LLY, NVO etc. The reason it’s up today is strong phase 2 obesity data. Nothing to do with genetic engineering. I think you meant to invest in VRTX and got lucky lmao, but congrats nonetheless!
I’m confused. VKTX is an obesity/NASH company with a GLP1/GIP agonist. Are you thinking of VRTX? … did you just make >1000% not knowing what you’re invested in?
They've been working on their gene editing drug for ages..I always wondered how it will turn out. (I'm a doctor, so may see this drug) Finally approved after years and years of study. One time shot for sickle cell disease and 2 other diseases. Cost: $3M. Issue is another company (VRTX/CRSP) has a competing drug for $2.2M. Does not have a black box warning (for side effect of blood cancer) , unlike BLUE'S product. Stock is priced low due to the black box warning and increased cost. Not making a play on it, but we'll see.
[absolutely](https://www.morningstar.com/stocks/obesity-drug-stocks-where-invest-now) LLY is up 140% over year, Norvo also blew up. Amgen, Roche, VRTX have drugs on way.
I like CRSP and NTLA personally. The bigger drugmakers will all be involved but I think VRTX could be one of the biggest winners (seems a bit too expensive to me right now, but it would not surprise me to see them at a $1T market cap in 10 years if the tech really takes off).
VRTX I meant but Vertiv isnt a bad idea. I once saw a movie a while ago that said something to the effect of everyone wants to bet on first, but if you throw in a few to 2nd best winning, you might find yourself winning more often... ( was about horse racing back in the 90s) but I liked it
no prob, MSFT, WMT, VRTX, APPL and V
Climbing: LYFT+10% VRTX META STNE MAR WELL TPR CSGS ALKS ADP
Huh? You asked me to find something that outperformed Meta and I referenced a stock we talked about earlier. It's also not a small cap. It's also one I own, so pretty easy to reference. How about VRTX? Up 120% since late 2021, so it also beat META. Gigantic moat and lots of innovation and future prospects. I still don't know what you're trying to prove. All I've said is there are non magnificent 7 companies that are great investments. That's all.
NTLA is much cheaper, and has a cure for an INVIVO solution for sickle cell disease. NTLA 2002 is in phase 3 this year. 2.4B market cap with two cures with 1B in cash, and 120mm Q/Q cash burn with only 25% ownership with REGN vs CRSP 40% VRTX ownership
I’m extremely new to investing and the stock market just as an fyi. I've been looking into value investing in the Biotech industry because I like losing money. I've been using valueinvesting.io and have looked at a few stocks. First, I found VRTX and saw it said it had negative upside so I just shorted it. That somehow worked but I started looking more into where that upside came from. I found ev/ebitda and started looking for stocks to buy. I found BllB with its share price extremely undervalued and high upside. I also saw the reason for this decrease was 2023 earnings. Their ev/ editba decreased insanely from this year alone down to 17.48. I purchased 250 shares at $240.83 ($60,207.50) and I was up 1.5% but now I'm down a little. Earnings are coming soon as well and I'm hoping for good news. I may now be slightly addicted. Did I make a smart move or am I just lucky? I've heard value investing doesn't work but it's worked well for my first two investments so idk?
VRTX has been great for a few years for me. A lot of big pharma is up against the combination of patent cliffs for blockbuster drugs and governments looking to reign in healthcare spending.
Is anyone looking at the $VRTX chart have any thoughts?!
>I Bought Lily and Vertex Pharmaceuticals (VRTX) stocks last Friday, looking forward to strong earning reports. They both delivered very strong reports and forward guidance last night and this morning, however, their stocks slide 1% and 3% today as of now. "Buy the rumor, sell the news." Stocks go up when investors are hoping for a good thing to happen in the future. When that thing actually happens, many investors will exit their position so that they can take profits.
There are stock markets where most investors are individual investors vs stock market like Wall Street where 80% of stocks and bonds are owned by institutions. Those behave very difference. Wall Street definitely knows the prospect of VRTX and how it will go in the future, and their knowledge is beyond all the publically available information. Individual investors definitely are at a disavantage. It might be easier for you if you just give up and buy ETFs or index funds.
You should also pay attention to some of the basic technical indicators. Based on simple moving average alone I would not consider VRTX a buy right now regardless of earnings etc. At the same time, I might consider PTON a strong buy.
Companies don’t just report their results and people react. They lay out plans months, quarters, even years ahead. VRTX is up 36% over a year. They beat earning and that’s what people expected it to do, that’s why it’s up 36%. Thinking after rising 36% and expecting it to pop again this recently is pretty optimistic. Dropping 1% short term has nothing to do with their long term plans. It’s more than numbers. You have to listen to the meeting where they lay out their short and long term plans. And if you’re an expert at pharmaceuticals or marketing or business or something you might be able to use your expertise to determine if their plan sounds good or not.
“What determines stock value” - supply and demand I think you are missing elements of investing. Eli Lily and Vertex are pharmaceutical companies which the entire industry is kinda notorious for basically being feast or famine. VRTX is at a 30 P/E and LLY is a whopping 121 which to me is insane (ie expensive) Per PTON. You are probably seeing people hoping to see either a rebound or willing to hold until it’s a profitable company but were waiting until it was cheap as possible. Also look at these companies market caps. The larger a company, the slower it tends to grow because it needs so much more grow than the dinky “startup” As Warren Buffet said “Nobody wants to get rich slowly” I don’t think you necessarily need to give up on individual stocks. You saw really good numbers in Vertex, understood past results and guidance. I can’t blame you for putting money down. However, you didn’t contextualize it. You need to understand market sectors, business models, valuation, amongst other things. And yes, the market tends to be forward looking Also it’s perfectly normal for a company to gain or lose 1-3% on any given trading day. You aren’t buying a ticker with a number attached. You are buying part of a business and you need to understand that business, its competitors and the economy as a whole. Sometimes also the type of investors that invest in a particular company can be used overly pessimistic or optimistic towards any types of news or results. Now if that is too much, or sounds like too much time/effort. Then sure go stick your money in VOO and forget about it.
Welcome to the stock market. It doesn't make sense. Earnings reports are always a crap shoot. Even if the numbers are solid, the stock can tank. It happens all the time, especially if the stock has risen substantially into the announcement. "Sell the news" is very common. When trading, I never hold through earnings, but as an investor I do, as long as my basis is much lower. I've owned VRTX for many years and didn't even know they were reporting. Today's drop is just a tiny blip for me as this is a long-term investment. I enjoy the challenge of figuring out individual stocks. If you buy right and sit tight, the returns can drastically outperform the indices. But if you cannot accept the randomness of individual stocks, then index funds are the way to go.
Each stock is driven by its narrative and specific expectations. LLY (obesity/Alzheimer’s) and VRTX (cystic fibrosis + pipeline?) are two examples of very different stories and those stocks have had a great run so far. Given your level of knowledge/research, stick with indexes.
The price that you buy at is based on future expectations for the company at that time. Afterwards, those future expectations can change, at which point the price also changes. When you bought VRTX and LLY, future expectations were very slightly higher than they are today On the other hand, when you bought PTON, future expectations were very slightly lower than they are today. There's also things like bond markets, foreign stock and bond markets, interest rates, etc that can affect the general stock market as opposed to affecting individual stocks.
>I am new to invensting. I Bought Lily and Vertex Pharmaceuticals (VRTX) stocks last Friday, looking forward to strong earning reports. They both delivered very strong reports and forward guidance last night and this morning, however, their stocks slide 1% and 3% today as of now. you don't have a magic crystal ball. if you thought there would be strong earning reports, so did other people, and they bought before you did, making the price go up. >what really determines the stock values? people buying and selling the stock. which you can never predict. >Maybe I should not pick individual stocks, and should just stick to VOO and forget about it. that's it
Look at it from a broader perspective. The stock market looks at future gains. Eli Lily has been doing very well for the last year, having a 100%+ gain, so there will be some pullbacks occasionally even though the quarterly report is good. Similar with VRTX, they have also gained 36% over the last year. For Peloton its the opposite - it has been beaten down to 28% of its value from a year ago - any news slightly more positive than what investors are expecting will pull it back up. If you keep holding onto companies with good cashflow and products you will get out on top, but in the shortterm it can go either way based on investor expectations of a company.
Farmer Jim pumping VRTX…like that too
VRTX Drugs and nerds plus massive profit margins. All of the flavors I like.
My portfolio is Bitcoin S & P Index Funds Google, Amazon, Adobe, Msft, Visa, Costco, LLY, VRTX, ANET. ​ it's working out.
I did i did and they’re looking good so far. I also got a small position $VRTX calls which did well!
VRTX earnings: Reports Q4 non-GAAP EPS $4.20, consensus $4.10 Reports Q4 revenue $2.52B, consensus $2.51B. Full year product revenue of $9.87 billion, an 11% increase compared to full year 2022 — — Company provides full year 2024 product revenue guidance of $10.55 to $10.75 billion — — CASGEVYTM approved in the U.S., Great Britain, the Kingdom of Saudi Arabia and Bahrain — Vertex on track to submit new drug applications (NDAs) to the FDA by mid-2024 for both VX-548 in Acute Pain and the Vanzacaftor Triple in CF — Broad and deep clinical-stage pipeline continues to advance across 10 disease areas "2023 was a transformative year for Vertex as we continued our strong performance, including 11% revenue growth, combined with significant advancement across the business. We expanded our leadership in CF, diversified our commercial opportunity with CASGEVY regulatory approvals in multiple regions, and rapidly advanced a broad pipeline with multiple additional near-term potential launch opportunities in disease areas outside of CF," said Reshma Kewalramani, CEO. "Our progress in 2023 lays the foundation for the anticipated regulatory submissions for the vanzacaftor triple and VX-548 by mid-2024 and sets us on a path to expand our business in CF and beyond, beginning with the commercialization of CASGEVY in multiple geographies."
NSSC carrying me. VRTX and MPC helping.
Calls or puts on VRTX?
I'm 19 and I have 25k saved up which I would like to invest. I'm studying in finance and I recently got an internship for a good firm, but I really don't know much about stocks yet. I have picked out a few potential stocks and I was wondering if I could get your opinion on them. Thanks! The stocks are : Comcast (CMCSA), Vertex Pharmaceuticals (VRTX), Novo Nordisk (NVO), Walt Disney (DIS) and Eli Lilly (LLY). I also own shares of KLA Corporation (KLAC) since August, which is now up 16.5%. Additionally, I would like to invest in renewable energy stocks if you have any suggestions.
Those are all solid companies, with LLY/NVO/VRTX being very different in type and circumstances from DIS/CMCSA, so interesting choices. KLAC is nothing but a money machines for the longterm. Renewable energy stocks have a bright future but the present is not so good because they usually rely on borrowing money, which is terrible when interest rates are high. Consider ETFs like TAN, GRID, QCLN and ICLN in the future but avoid them now. Also, instead of individual stock picking, consider establishing base positions with broad market or industry ETFs rather than only pick stocks.
I'm 19 and I have 25k saved up which I would like to invest. I'm studying in finance and I recently got an internship for a good firm, but I really don't know much about stocks yet. I have picked out a few potential stocks and I was wondering if I could get your opinion on them. Thanks! The stocks are : Comcast (CMCSA), Vertex Pharmaceuticals (VRTX), Novo Nordisk (NVO), Walt Disney (DIS) and Eli Lilly (LLY). I also own shares of KLA Corporation (KLAC) since August, which is now up 16.5%. Additionally, I would like to invest in renewable energy stocks if you have any suggestions.
I'm 19 and I have 25k saved up which I would like to invest. I'm studying in finance and I recently got an internship for Brookfield Renewable, but I really don't know much about stocks yet. I have picked out a few potential stocks and I was wondering if I could get your opinion on them. Thanks! The stocks are : Comcast (CMCSA), Vertex Pharmaceuticals (VRTX), Novo Nordisk (NVO), Walt Disney (DIS) and Eli Lilly (LLY). I also own shares of KLA Corporation (KLAC) since August, which is now up 16.5%. Additionally, I would like to invest in renewable energy stocks if you have any suggestions.
Calls- LLY, CAT, VRTX, MCK, AMGN, YUM
Beta of .37 and recent downgrade. No thanks (and no thanks to a majority of biotech garbzzz). https://finviz.com/quote.ashx?t=VRTX&p=d
I bought call and put options on $TSLA. The options will get more expensive in both directions...so why not? easy money. Plus I will make some cash in the AM either way. I am buying the JULY Natural Gas Futures. I think these are gonna make some serious cash i the next two months. I closed my snowflake calls. Still have puts on VRTX and ANF Looking at Service Now Calls.
Small aside...VRTX had great news to report about their non-opioid pain killer at the JP Morgan health care conference last week. They're basically viewing this as a chronic pain treatment, which means recurring revenue for them. As of now, they're not trying it for major operations or extreme pain. However, if effective, this would be a gigantic opportunity for the company. There's a reason the stock has been on fire since they announced their clinical trial results. It's nice as an investor because this was always my lottery ticket joined to a great company. The market is finally catching on.
CRSP FDA approval of second gene-editing treatment with partner VRTX.
Both CRSP and VRTX are working on functional cures (in the clinic) for T1D. Are insulin manufacturers ''trying tooth and nail'' to stop either? No.
Haha same here, happy to share of course but now need to figure out how to reclaim those taxes if possible. (Also I foolishly sold some VRTX on Dec 7 to pull off some of this so… 🤣)
CRSP CRISPR Therapeutics AG Profit margin -54,271.70% VRTX Vertex Pharmaceuticals, Inc. Profit margin 37.20% Can't figure that out?
Truthfully I think the best equity portfolio for the long term is 60% SCHG, 20% SCHD, 20% VIGI. As far as individual stocks go my top 6 picks would be MELI, ALG, EG, GOOGL, BRK-B, VRTX. Honorable mention to CRSP and NTLA as I think they are the future of medicine but wouldn’t recommend them as a core holding. ALG is my largest individual stock holding and I believe they have a very bright future ahead so long as they continue making good value roll up acquisitions.
I held VRTX throughout 2020 and 2021 then panic sold for 20% loss. 1 month later VRTX started moving up and never looked back. One of the worst decisions of my investing career. I will never touch this stock again lol but good luck to you.
This isn't a late move. Sickle Cell is one of their smallest programs and in the Q3 earnings an Executive wasn't even sure how much they will make from it as it is a complicated/time consuming treatment. The stock did not move much from the CRSP/VRTX approval in Dec. Their main stay is CF and the next one will be PAIN which in total (for all indications they are pursuing) is a $4B opportunity for the company. One of the biggest moves in 2023 was due to success with P2 for Neuropathic Pain for VX-548 (another indication for the drug).
Youre betting on experiments. You have no idea what the data will show and it is expensive. You really need to be in the field to understand. I work for a CRO and work with hundreds of biotech companies. I follow their pipeline. For example, the beginning of this year I bought 150 shares of Vrtx and 1000 shares of CYTK...both popped by the end of this year bc I knew which of their compounds are going to be successful. I'm selling out CYTK just ahead of them submitting their next compound for FDA market approval but holding VRTX. VRTX is a machine of a company
With long duration rates falling and rate cuts forecasted indicating that money markets, HYSAs, CDs, bonds, etc. will no longer be as attractive, I’m rotating back into growth stocks. The big 7 and tech in general is seeing a quick return to ATHs which means there may not be much juice left to squeeze in growth tech. Which means I need to look elsewhere for rate-dependent growth industries. For me, I spend a lot of time researching biotech stocks because fruitful labor and effort in this industry can give you an edge over most investors except other dedicated researchers and institutions. I have paid my dues with small cap biotech and now lean toward med-to-large size companies with three checkboxes that must be filled. 1. Follow the money. People and institutions much smarter and powerful than I must be heavily invested and back the company. 2. A Strong balance sheet. The company needs to have a history of hitting expected timelines because excessive delays are what shake market confidence and lead to dilution. 3. A strong, relatable narrative where the end story is higher valuations. This means the market cap needs to be priced below the NPV of what major investors, the company, and myself consider to be the median expectation of future revenue. What the product achieves needs to be easily understood to justify large, seemingly unlimited upside to help fuel sentiment. For me at the moment, that stock is CRSP, CRISPR Therapeutics, and their partner company VRTX. CRSP has first-to-market advantage in a space where trust and reputation will be king because gene editing is highly complex and potentially dangerous. With just their sickle cell treatment, the addressable market they are focusing on in the short term is estimated to be worth 32 billion by 2030. This alone justifies their market cap up to 8 billion or so, but the real homerun will come from their several treatments in their rapidly advancing pipeline. I encourage everyone to consider the gene editing as the next frontier of medicine and curative treatments. Do you remember the hype around the human genome project and what this research could eventually achieve with curing diseases and even enhancing human condition beyond cures? Well that door of opportunity has opened and now that the first gene editing cure is on the market, the industry will boom and the exponential progress will be that much more tangible to the broader public. I could write a novel on what is to come, but plenty is already out there. A good start would be looking at CRSP’s pipeline: https://crisprtx.com/pipeline
VRTX and CRL have been the big winners on the treatment roll out and manufacturing.  (and me, for knowing this)
Sunshine and warm breezes make me feel reckless. 200 shares of VRTX at $ 401.50
Yeah, they already negotiated royalties for the patents pertaining to cas9. Something like $50m upfront + some conditional amount (can't remember exactly what the terms were off the top of my head). As far as a current valuation, VRTX most recently paid $900m for 10% of cas9. This was long prior to approval and I'm sure people would argue higher/lower, but let's just use that number. CRSP retains 40%, which would be valued at $3.6b. They also have just under $2b cash on the balance sheet. Just cash + cas9 should give them a value of $5.6b, which is higher than their current market cap of just under $5b. They're currently being priced as if the rest of their pipeline holds negative value to the company. I averaged into them at around $53-54, most recently bought a bunch at $38.80 because that seemed ridiculous.
I may be wrong but CRSP/VRTX just made a deal with EDIT for cas9 which plays a huge role in editing. While your statement does show the risk in all these gene editing companies holding different patents, it does show that companies are willing to make deals and they need each other
VRTX, Vertex Pharma, unbelievable pipeline, monopoly on cystic fibrosis, Pain pills none opioid, great trial. Great ongoing trial for diabetes , great trials on kidney, just had first crisper drug passed , gene editing, with crisper therapeutic!! Owned it for a couple years, can’t find anything bad about company! Huge cash flow!! No debt!!
Apparently shooting fish in a barrel doesn’t even require hitting a fish directly, it’s just the bullet’s pressure wave upon the water. With that info, I emptied a few clips in premarket loving more long on: * RKT * GDX * XBI (thanks for the VRTX exposure) * TDOC * LYFT * BXP * SPG * PGY * FVRR
You’ve already made the bear case. Raging bull market is not a time to consider stocks at new lows. Cheap stocks are cheap for a reason, even if you don’t know the reason or disagree with the market’s price. If you want to invest in pharmaceutical companies there are so many better options. Yesterday I would have said VRTX, but that ship sailed this morning.
Good: I own VRTX stock Bad: I wrote ccs on it😩
Calls on ON, XOM, F, VRTX, CVX, CFG. SPY puts are toast tho.
I believe opiates are known to get you to "bliss". It's possible this will fill the niche between ibuprofen and the bliss drugs. Things like root canals that probably don't need powerful pain killers. I read a write up on it a month or so ago, but can't find the link, unfortunately.....it came over my news feed as I own VRTX.
Selling CRSP a few days ago, albeit at a loss, is making me feel like less of an idiot for buying into the hype. Thankfully I bought and sold VRTX at a healthy profit that more than made up for it. Biotechs, even when a “sure thing” are way too much of a gamble.
All the girls at the dentist's office already wearing their Friday-going-out makeup. Was a little weird, actually. CRSP 70c VRTX 350c GT 14c ON 70c
I mean if all fundamentals stay the same then literally every stock I own I would scoop up at 50% off. If I like it enough to hold/buy now I certainly would buy more at 50% lower. So there’s about 50 companies this applies to. But then there are some I don’t own that I have on a watchlist. Most of which I think are too pricey to enter. From the watchlist I’d get $MELI, $VRTX, $COST, $WINA, and maybe $SNOW but I haven’t looked into it much.
VRTX for the win in healthcare.
I am heavily invested in tech and took advantage of the unsustainable gains. Some of my most risky positions that I would like to offload are AVGO, NVDA, and PANW Im up about 33% YTD across all accounts but I know that shit isn’t sustainable. I work in tech so I know what’s hot and understand the products. My second is healthcare. Lately I’ve been looking at VRTX, MOH, and just plain old buying the S&P
Still room to run....VRTX with the expected FDA approval of their CRISPR-based sickle cell treatment next week, after approval in the UK this week.
VRTX and CRSP saving the day
First sickle cell disease gene editing therapy approved in the UK $CRSP $VRTX
VRTX and CRSP get approval for sickle cell treatment in the U.K. https://www.ft.com/cms/s/ab87cac0-4b13-4b08-a6b7-77875a77dc55,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo It's the first crisper treatment approved anywhere.
>They have also outperformed all other stocks in terms of growth, profit margins and forward EPS growth, and have stronger balance sheets. I'm not sure this is true. VRTX has no debt and 10% of its market cap in cash. That's a strong balance sheet. They don't have the most EPS growth this year https://finviz.com/screener.ashx?v=121&f=idx_sp500&o=-epsyoy Or next https://finviz.com/screener.ashx?v=121&f=idx_sp500&o=-epsyoy1 Or performance over the last year https://finviz.com/screener.ashx?v=141&f=idx_sp500&o=-perf52w So none of your arguments hold up about the magnificent 7. They are great companies, but not the only great companies.
Nevermind, found a source, but doesn't this mean we should be investing in CRSP and VRTX? Of course the approval of these treatments would "pave the way" for VERV, but isn't an invesntment in CRSP and VRTX going to pay off better on Dec 8?
around 7-8 dollars would be very bad for the stock but FDA approval deadline for CRSP / VRTX exacel. The first genetic treatment of it's kind and will pave the way for VERV at the 8th of december will make it rise no mather what same with the xbi index
Vertex Pharmaceuticals $VRTX sees \~4% decline amid concerns over a mid-stage trial of the company’s non-opioid pain candidate, VX-548. The stock is rated buy on the app with an AI score of 7.7/10. \- Trend: Biologics outpace non-biologics in growth, dominating over 50% of the market, while unbranded generics see declining revenues despite increased prescriptions. \- Thesis: $VRTX’s strategy for independent efficacy remains strong. \- Financials: EBITDA margin 47% vs 5% industry, Rev growth (fwd) 11% vs 6% industry What do you guys think of their analysis/rating? I want to understand if I can really make money from their recommendations...TIA
FDA approval deadline for CRSP / VRTX exacel. The first genetic treatment of it's kind and will pave the way for VERV
VRTX has had a nice selloff since earnings. Becoming reasonably priced, with a nice upside if either of the two new treatments gets approved.
VRTX - I expect the development of a key medical treatment that will significantly improve the quality of life for large population groups.
VRTX popped today in anticipation of earnings then gave it all back after reporting.
VRTX - Vertex Pharmaceuticals 3Q Adj EPS Beats Estimates: ∙ Adj EPS $4.08, est $3.91 ∙ Adj net income $1.06b, est $1.03b ∙ Trikafta net revenue $2.27b, est $2.25b ∙ R&D expenses $810.0m, est $759.4m Vertex today raised its full year 2023 CF product revenue guidance to approximately $9.85 billion. Cash, cash equivalents and total marketable securities as of September 30, 2023 were $13.6 billion, compared to $10.9 billion as of December 31, 2022. The increase was primarily driven by strong revenue growth and operating cash flow, partially offset by our payments to Entrada Therapeutics, CRISPR Therapeutics and other collaboration partners, repurchases of our common stock pursuant to our share repurchase program, and income tax payments.
I own VRTX. There was an article the other day in Barron's (I can't find the link right now) arguing that the market had not yet priced in either their sickle cell (impressive) or non-opioid pain killer (gigantic) being approved. The sickle cell decision is expected next month, and it looks like the market might be starting to price in an approval. Long story short, I've been holding it for a few years and don't plan on selling anything.
I dont like VRTX because they are big meanies to my RPRX
VRTX earnings today. This is a blockbuster company with a couple blockbuster drugs coming up. I wonder if there’s a ceiling for this company honestly. I’m putting in about 350 but I might be missing out today.
I bought VRTX undervalued 20% according to my own math. Sold for profit at 25%, which was my target, but then it kept going up an additional 20% I know its one of the rules not to look at past investments with regrets, but my initial estimate was indeed 20% higher and I thought it was too optimistic so I downscaled my expectations T.T
First off, other than maybe ILMN, the companies you’ve listed are all very nascent and therefore I’m very risky. If you’re just looking to 2x your investment, stick with more mature companies like TMO (more on them below). These other companies are small enough that, if it hits, you’re probably looking at 10-100x over a decade or less. I discuss this a bit later too, but suffice it to say, if you go that route, be ready to lose 90% of your investment. OK, on to the companies: ILMN is fairly mature sequencing tech, and therefore stands apart from the others. Another commenter already spoke on them, and I agree with their stance. You could throw a few other companies in that pool alongside PACB, such as Agilent, TXG, and Oxford Nanopore. These companies are primarily focused on still new-ish tech, and don’t have a moat anywhere near as deep as TMO, so somewhat risky. TMO, btw, has been growing pretty rapidly, is very stable, and is currently at a low, so it’s a much safer bet than anything else on this list. It also has a good track record for payout (IIRC 2x financials over four years or so, which is a big deal for such a mature company). The others are all therapeutics based on very new tech, and so are very risky. One or two of these (even one that isn’t listed), will probably hit it out of the park and explode. Some will get bought by the likes of PFE or Merck. Most will crash and burn. I currently own CRSP, but it’s a very small part of my portfolio. Held EDIT and NTLA very briefly but luckily dumped them before they really started crashing. After a fair amount of DD I ended up investing in VRTX instead. It’s a much more mature company with a more mature pipeline and decent IP that isn’t afraid to try out new tech. VRTX is partnering with CRSP on their CRISPR-based blood disease targeted therapeutics. In other words, they’ll bounce if CRSP hits a home run in this field, but also won’t collapse on a single strikeout. Out of all of the CRISPR-based therapeutics companies, CRSP probably has the easiest path to success given their focus on very well-characterized blood-based disease targets/pathways. That is to say, it’ll be much easier for them to clear FDA approval than anyone else.